From the Division of Plastic, Maxillofacial, and Oral Surgery and the Departments of Surgery and Radiation Oncology, Duke University Medical Center; the Department of Biostatistics and Bioinformatics, Duke University; and the Duke Cancer Institute.
Plast Reconstr Surg. 2019 Sep;144(3):347e-357e. doi: 10.1097/PRS.0000000000005899.
Complications from breast reconstruction may delay postmastectomy radiation therapy and impact breast cancer outcomes. The authors hypothesized that immediate breast reconstruction may be associated with delays in the initiation of radiation, but that this delay would not significantly impact overall patient survival.
Using the National Cancer Database, the authors identified women with breast cancer who underwent mastectomy and received postmastectomy radiation therapy. Delayed radiation was defined as treatment initiated 6 months or more after surgery in patients who received adjuvant chemotherapy or 12 weeks or more after surgery in patients who received neoadjuvant or no chemotherapy.
Women undergoing breast reconstruction had an increased time to postmastectomy radiation therapy, 154 days versus 132 days (p < 0.001), and were more likely to experience a delay in initiating radiation (OR, 1.25; 95 percent CI, 1.188 to 1.314). Other factors associated with delayed radiation included increased Charlson/Deyo scores, neoadjuvant chemotherapy, nonprivate insurance, and black race. Cox proportional hazards models revealed no evidence of a reduced adjusted overall survival in the immediate breast reconstruction group (hazard ratio, 0.836; 95 percent CI, 0.802 to 0.871; p < 0.001). Restricted cubic spline analysis identified the threshold number of days at which the start of radiation began to impact survival at 169 days (95 percent CI, 160 to 190 days), 75 days (95 percent CI, 42 to 90 days), and 71 days (95 percent CI, 41 to 90 days) in patients undergoing adjuvant, neoadjuvant, and no chemotherapy, respectively.
Immediate breast reconstruction is associated with a modest delay in initiating postmastectomy radiation therapy but does not impact overall survival.
CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, III.
乳房重建的并发症可能会延迟乳腺癌术后放疗,并影响乳腺癌的治疗效果。作者假设即刻乳房重建可能与放疗启动延迟有关,但这种延迟不会显著影响患者的总体生存率。
作者利用国家癌症数据库,确定了接受乳房切除术并接受术后放疗的乳腺癌患者。延迟放疗定义为接受辅助化疗的患者在手术后 6 个月或以上开始治疗,或接受新辅助或无化疗的患者在手术后 12 周或以上开始治疗。
接受乳房重建的患者术后接受放疗的时间延长,为 154 天,而不是 132 天(p<0.001),并且更有可能出现放疗启动延迟(OR,1.25;95%CI,1.188 至 1.314)。其他与放疗延迟相关的因素包括Charlson/Deyo 评分升高、新辅助化疗、非私人保险和黑人种族。Cox 比例风险模型显示,即刻乳房重建组的调整后总生存率无降低的证据(风险比,0.836;95%CI,0.802 至 0.871;p<0.001)。受限立方样条分析确定了开始放疗影响生存的时间阈值,分别为 169 天(95%CI,160 至 190 天)、75 天(95%CI,42 至 90 天)和 71 天(95%CI,41 至 90 天),这些天数适用于接受辅助、新辅助和无化疗的患者。
即刻乳房重建与术后放疗启动的适度延迟相关,但不会影响总体生存率。
临床问题/证据水平:治疗性,III 级。